NASDAQ OMX

Taconic Biosciences Sponsors Custom Model to Support Kabuki Syndrome, a Rare Disorder Causing Intellectual Disability

Dela

HUDSON, N.Y., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered rodent models and associated services, is funding the development of a custom mouse model to study Kabuki syndrome, a rare genetic disorder. Taconic is donating model generation services as a third-time sponsor of the Rare Disease Science Challenge, BeHEARD. Hosted by the Rare Genomics Institute, the Rare Disease Science Challenge is an annual event in which industry sponsors donate services to accelerate rare disease research.

Characterized by mild to moderate intellectual disability, stunted growth, immune dysregulation, and hearing loss, Kabuki syndrome is caused by mutations in the KMT2D or KDM6Agenes. Taconic will use CRISPR/Cas 9 gene editing technology to develop the first Kmt2d missense mouse model of Kabuki syndrome and generate a cohort of mice for study. In parallel, Taconic will cryopreserve and store the mouse line.

"Taconic recognizes the vital role mouse models play in understanding the mechanisms of rare diseases and the challenges of funding their research," said Bob Rosenthal, CEO, Taconic Biosciences. "Taconic is committed to advancing rare disease research through efforts such as sponsorship of the BeHEARD challenge and donation of an integrated solution of model generation, breeding and cryopreservation capabilities."

Teresa Luperchio, PhD, a postdoctoral fellow in the laboratory of Hans Bjornsson, MD, PhD, director of the Epigenetics and Chromatin Clinic, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, will employ the Taconic model. Dr. Bjornsson's lab previously characterized a mouse model carrying a loss-of-function variant of the Kmt2d gene and demonstrated reversal of some learning and memory deficits using therapeutic strategies. However, the initial mouse line models only a subset of individuals with Kabuki syndrome. Taconic will generate a Kabuki syndrome mouse model based on a patient-specific missense mutation. This will enable investigators to assess whether therapies they are developing can reverse disability in a wider spectrum of the Kabuki syndrome patient population.    

"The model will be invaluable in moving the field closer to treating what has been viewed as an untreatable disorder. Experience with our first mouse model showed that for patients with the KMT2D mutation, the disease may be treatable in humans," Dr. Bjornsson said. "We hope the Taconic model will demonstrate this capability in an expanded patient population, allowing us to employ a single therapeutic strategy for all Kabuki syndrome type 1 patients." 

"Taconic's ability to develop a patient-specific model was essential. Generating a model that closely represents what is seen in patients is critical for translating our findings from the bench to the clinic," Dr. Luperchio says.

To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US or +45 70 23 04 05 in Europe, or email info@taconic.com.

To learn about the BeHEARD Project, visit http://www.raregenomics.org/beheard-competition/.

About Taconic Biosciences, Inc.
Taconic Biosciences is a global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

PayByPhone appoints Andreas Gruber as new President and CEO20.4.2018 00:19Pressmeddelande

VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it will appoint Andreas Gruber as president and Chief Executive Officer effective June 1st, 2018. Francis Dupuis, the former President and CEO, will take over a position in Germany with parent company Volkswagen Financial Services AG. To provide additional impetus to the PayByPhone board, two new board positions have been created and as a result Maggie Clay (CFO) and Catherine Scott (Legal Counsel) will be appointed effective June 1st, 2018. During his time at PayByPhone, Francis led the business through significant growth and organizational change and leaves the company well positioned for continued success. "We would like to thank Francis for his strong leadership and look forward to building on his experience within Volkswagen Financial Services," Gerd Künne, Vice-President of mobility unit at Volkswagen Financial Services, said. Francis is e

Progress and Potential for Achieving Cleaner Air on a Global Basis20.4.2018 00:09Pressmeddelande

Adoption of New Generation Diesel Technology Delivers Rapid Clean Air Benefits New understanding of global air quality highlights the need for technologies like new-generation diesel engines, which are capable of accelerating emissions reductions WASHINGTON, April 19, 2018 (GLOBE NEWSWIRE) -- Recent reports highlighting air quality conditions in the United States (State of the Air) and globally (State of Global Air 2018) celebrate the progress made in developed and developing countries, but also emphasize significant disparities in progress toward reducing levels of key pollutants such as particulate matter and ozone. "Achieving continued clean air progress while also sustaining economic growth is possible. Cities and countries must move to proven cleaner engines and fuels," said Allen Schaeffer, executive director of the Diesel Technology Forum. "We can and should bring the tremendous benefits of new technology diesel engines to communities and countries large and small around the wor

SD-WAN for Office 365: Aryaka Helps eLearning company, City & Guilds Group, Improve Office 365 Application Response Time19.4.2018 18:54Pressmeddelande

Aryaka's Global SD-WAN reduces time for global users to open SharePoint files from 10 to 0.05 seconds; Outlook performance improves 9x worldwide LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, announced today its SD-WAN technology has enabled City & Guilds Group, a worldwide leader in workplace skills, eLearning, and executive coaching, to achieve faster Office 365 application response times leading to an increase in productivity and better collaboration between users in Europe and Asia-Pacific. Headquartered in London, the City & Guilds Group works with education providers, governments and major corporations to help shape and support skills development for employers in over 100 countries. Team members of the company are similarly scattered around the world and primarily collaborate using Microsoft Office 365 applications, but many remote users were struggling to access the group's instance of Office 365 hosted in Dublin. For example, it could ta

Canacol Energy Ltd. Announces Private Offering of Senior Notes19.4.2018 16:23Pressmeddelande

CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) is pleased to announce that it intends, subject to market and other conditions, to offer senior unsecured notes (the "Notes") in a private placement to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act and pursuant to certain prospectus exemptions in Canada (the "Offering"). The Notes will be fully and unconditionally guaranteed by certain subsidiaries of Canacol. The interest rate, redemption prices and other terms of the Notes are to be determined upon pricing of the Offering. Canacol intends to use the net proceeds from the Offering: (i) to repay the outstanding amounts borrowed under its credit facility; (ii) to pay fees and expenses of the O

FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00Pressmeddelande

New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part

SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00Pressmeddelande

SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum